Journal
BREAST CANCER
Volume 22, Issue 6, Pages 602-607Publisher
SPRINGER JAPAN KK
DOI: 10.1007/s12282-014-0526-2
Keywords
eIF-5A2; Chemoresistance; Doxorubicin; Breast cancer
Categories
Funding
- Science and Technology Planning Project of Zhejiang Province, China [2012KYA071]
Ask authors/readers for more resources
Background The eIF5A2 gene (encoding the eukaryotic initiation factor 5A2) located at 3q26 is a putative oncogene that is overexpressed in colon and rectal carcinomas, lung cancer and hepatocellular carcinoma. EIF5A2 overexpression correlates significantly with tumor metastasis and is an adverse prognostic marker. However, eIF-5A2 overexpression in breast cancer and its effect on chemotherapy are unknown. Methods We measured eIF-5A2 expression and doxorubicin sensitivity in different human breast cancer cell lines (Bcap-1937, HCC1937, and MCF-7). To investigate a role for eIF-5A2 in chemoresistance, cells were treated with eIF-5A2-siRNA, exposed to various concentrations of doxorubicin, and toxicity was assayed by CCK-8 (cell counting kit). Results The eIF-5A2 expression levels varied among breast cancer cells. Higher expression levels correlated with decreased doxorubicin sensitivity. Silencing of eIF-5A2 significantly improved doxorubicin toxicity in all three breast cancer cell lines. Conclusion This study shows that eIF-5A2 plays an important role in doxorubicin chemoresistance in breast cancer cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available